ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 109 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2021. The put-call ratio across all filers is 3.95 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $878,674 | -38.0% | 145,717 | +14.7% | 0.00% | – |
| Q1 2024 | $1,416,463 | +17.9% | 127,037 | +57.4% | 0.00% | – |
| Q4 2023 | $1,201,445 | +164.1% | 80,688 | +69.6% | 0.00% | – |
| Q3 2022 | $455,000 | -95.0% | 47,586 | -95.8% | 0.00% | -100.0% |
| Q2 2022 | $9,126,000 | -80.8% | 1,128,101 | -59.9% | 0.00% | -75.0% |
| Q1 2022 | $47,486,000 | -40.7% | 2,809,826 | -24.6% | 0.01% | -38.5% |
| Q4 2021 | $80,122,000 | -71.9% | 3,728,330 | -3.6% | 0.01% | -73.5% |
| Q3 2021 | $285,627,000 | +80.3% | 3,867,142 | +33.5% | 0.05% | +88.5% |
| Q2 2021 | $158,402,000 | -19.3% | 2,896,890 | +8.8% | 0.03% | -25.7% |
| Q1 2021 | $196,262,000 | +14.8% | 2,661,562 | +34.2% | 0.04% | +12.9% |
| Q4 2020 | $170,943,000 | +337.8% | 1,983,106 | +91.7% | 0.03% | +287.5% |
| Q3 2020 | $39,042,000 | – | 1,034,528 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |